In a Phase 1 trial, the selective GLS1 inhibitor IACS-6274 combined with paclitaxel and bevacizumab showed early signs of activity in advanced platinum-resistant ovarian cancer. Investigators reported confirmed partial tumor responses in nine of 13 evaluable patients and presented a safety profile supporting continued development of the regimen. The signal extends the glutamine-addiction strategy into combination settings where conventional chemotherapy is increasingly limited by resistance mechanisms.